Texas Oncology, P.A. Texas Oncology PA (3)
Welcome,         Profile    Billing    Logout  
 5 Trials 
13 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Richey, Stephen L
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
Sullivan, Nori
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Recruiting
2
140
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
10/25
09/26
MAMMOTH, NCT05198804 / 2021-004161-13: A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Hourglass Jul 2024 - Dec 2024 : Topline data for platinum resistant ovarian cancer
Active, not recruiting
1/2
117
Europe, US
ZN-c3, Niraparib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, K-Group Beta, Inc.
Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
05/25
05/25
NCT05705505: Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Recruiting
1/2
60
US
Narazaciclib, ON 123300, HX-301, Letrozole 2.5mg, Femara
Onconova Therapeutics, Inc.
Endometrioid Endometrial Cancer
01/26
02/26
NUV-868-01, NCT05252390: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Recruiting
1/2
657
US, RoW
NUV-868, Olaparib, Lynparza, Enzalutamide, Xtandi
Nuvation Bio Inc.
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
06/26
11/26
UPGRADE, NCT04907968: Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Terminated
1
31
US
XMT-1536 (Upifitamab Rilsodotin), XMT-1536, UpRi, Carboplatin
Mersana Therapeutics, IQVIA Biotech, PSI CRO
Platinum-sensitive Ovarian Cancer (UPGRADE-A)
10/23
10/23
NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Recruiting
1
187
Europe, US
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Toray Industries, Inc
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
03/25
03/25
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Active, not recruiting
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Rodriguez, Cintya
No trials found

Download Options